Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 23 of 24 pages ‹ First < 21 22 23 24 >
HSL4038
Berube B.
Who regulates drug advertising in Canada
Canadian Pharmaceutical Journal 1990; 123:402, 418
HSL4039
Ethical responsibilities of physicians in their dealings with pharmaceutical companies
Annals of the Royal College of Physicians and Surgeons of Canada 1990; 23:45-48
HSL4040
Blouin , C .
Hypertension and eating habits
Canadian Medical Association Journal 1990; 143:460-461
HSL4041
Bricker EM.
Industrial marketing and medical ethics
New England Journal of Medicine 1990; 322:64
HSL4042
Burkle JS.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990; 113:407-408
HSL4043
Bushe CJ.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990; 322:65
HSL4047
Canavan B.
Forging the alliance: CME’s relationship with industry
Journal of Continuing Education in the Health Professions 1990; 10:123-128
HSL4048
Chetley A.
A healthy business? World health and the pharmaceutical industry
Zed Books 1990;
http://www.amazon.com/Healthy-Business-Health-Pharmaceutical-Industry/dp/0862327350/ref=sr_1_1/102-1249992-1219339?ie=UTF8&s=books&qid=1174978013&sr=1-1
HSL4049
Chren MM, Landefeld CS, Murray TH.
Doctors, drug companies, and gifts
JAMA 1990; 263:2178-2179
HSL4050
Cockerill R.
Report on the 1989 survey of the dispensing practices and attitudes toward prescription drugs of Ontario pharmacists
1990;
HSL4052
Double standard labelling of pharmaceuticals sold in Thailand
Drug Study Group 1990; 3
HSL4053
Duffin JM.
Junk mail
Canadian Medical Association Journal 1990; 142:708
HSL4055
Erola J.
A sample response
Canadian Medical Association Journal 1990; 143:129
HSL4056
Feather KR.
Persantine advertisement: artistic license or misleading implication?
JAMA 1990; 263:659
HSL4057
Gall JM.
Medifacts tapes and general practice
Canadian Family Physician 1990; 36:419
HSL4058
Gelbart H.
Doctors, drug companies, and gifts
JAMA 1990; 263:2177
HSL4059
Glass AR.
Industrial marketing and medical ethics
New England Journal of Medicine 1990; 322:64
HSL4060
Goldstein M.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990; 113:407
HSL4062
Gorski TN.
Doctors, drug companies, and gifts
JAMA 1990; 263:2177
HSL4065
Herxheimer A.
Medicines in francophone Africa
Lancet 1990; 335:1449-1450
HSL4067
Hume AL.
Doctors, drug companies, and gifts
JAMA 1990; 263:2177-2178
HSL4068
Jason KM.
Persantine advertisement: artistic license or misleading implication?
JAMA 1990; 263:658-659
HSL4070
Jones K.
Advertising acyclovir
Lancet 1990; 335:732
HSL4072
Kimbel KH.
Advertorials?
Lancet 1990; 336:496
HSL4073
Lexchin J.
Disinformation from pharmaceutical company representatives
Canadian Medical Association Journal 1990; 143:370
HSL4074
Lexchin J.
Drug makers and drug regulators: too close for comfort: A study of the Canadian situation
Social Science and Medicine 1990; 31:1257-1263
HSL4075
Lexchin J.
The portrayal of the elderly in drug advertisements: a factor in inappropriate prescribing?
Canadian Journal on Aging 1990; 9:296-303
HSL4076
Lexchin J.
Prescribing by Canadian general practitioners: review of the English language literature
Canadian Family Physician 1990; 36:465-470
HSL4078
McSherry J.
Medifacts tapes and advertising
Canadian Family Physician 1990; 36:850
HSL4079
Strom B.
Notes of the American Society for Clinical Pharmacology and Therapeutics: Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes
Clinical Pharmacology and Therapeutics 1990; 48:598
HSL4080
Morris LA, Banks DB.
New issues in drug advertising and labeling: the five advertising end-runs
Drug Information Journal 1990; 24:639-646
HSL4082
Ethical aspects of phamaceutically based clinical investigation
Annals of the Royal College of Physicians and Surgeons of Canada 1990; 23:436-438
HSL4084
Nidiry JJ.
Doctors, drug companies, and gifts
JAMA 1990; 263:2178
HSL4085
Noble RC.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990; 113:408
HSL4086
Noble RC.
The pizza parade
Annals of Internal Medicine 1990; 112:237
HSL4087
Odenbach E.
Collaboration with commercial interests in continuing medical education
Journal of Continuing Education in the Health Professions 1990; 10:293-301
HSL4088
Peay MY, Peay ER.
Patterns of preference for information sources in the adoption of new drugs by specialists.
Soc Sci Med 1990; 31:(4):467-76
HSL4090
Potter HP.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990; 113:407
HSL4091
Pye J.
“Disinformation” from pharmaceutical company representatives
Canadian Medical Association Journal 1990; 142:1178
HSL4093
Relman AS.
More on sex and racial bais in pharmaceutical advertisements
New England Journal of Medicine 1990; 322:1534
HSL4094
Rendle MA.
Zopiclone (Imovane): evaluation in general practice
New Zealand Medical Journal 1990; 103:225
HSL4096
Robertson WO.
Throw-away journals
Canadian Medical Association Journal 1990; 142:708
HSL4097
Robinson WK.
A sample argument
Canadian Medical Association Journal 1990; 143:611
HSL4098
Rodwin MA.
Industrial marketing and medical ethics
New England Journal of Medicine 1990; 322:64
HSL4099
Roeg N.
The other drug trade
Adbusters 1990; 1:(4):80-87
www.adbusters.org/adbusters/
HSL4100
Russell R, Nelson PJ, Ohri L.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990; 322:64-65
HSL4103
Scherr L.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990; 113:408
HSL4109
Shepherd R.
Junk mail
Canadian Medical Association Journal 1990; 143:14
HSL4110
Shickman MD.
CME’s relationship with industry
Journal of Continuing Education in the Health Professions 1990; 10:189-190
HSL4111
Shulkin D.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990; 113:407
HSL4113
Solomon SD.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990; 322:65
HSL4114
Squires BP.
Editors and advertisers
Canadian Medical Association Journal 1990; 143:167
HSL4115
Squires BP.
PAAB: a lesson in self-government
Canadian Medical Association Journal 1990; 143:1151
HSL4116
Stein U.
Ginkgo biloba extracts
Lancet 1990; 335:475-476
HSL4118
Information or communication? A consumer study of television advertising
Taylor Nelson Research 1990;
HSL4119
Thomas M, Lexchin J.
Responsiveness to physicians' requests for information concerning drug interactions: a comparison of brand and generic companies.
Soc Sci Med 1990; 31:(2):153-7
HSL4122
Tilyard MW, Dovey SM.
Placement of advertisements
New Zealand Medical Journal 1990; 103:382
HSL4123
Timpany J.
A sample argument
Canadian Medical Association Journal 1990; 143:129
HSL4124
Tomson G, Angunawela I.
Patients, doctors and their drugs. A study at four levels of health care in an area of Sri Lanka
European Journal of Clinical Pharmacology 1990; 39:463-467
HSL4125
Tomson G, Weerasuriya K.
'Codes' and practice: information in drug advertisements--an example from Sri Lanka.
Soc Sci Med 1990; 31:(7):737-41
HSL4126
Van HR, Mazmanian PE, Osborne CE.
Commercial support for CME courses sponsored by medical schools
Journal of Continuing Education in the Health Professions 1990; 10:197-210
HSL4127
Venturelli J.
Medical ethics: a dilemma at our doorstep
Annals of the Royal College of Physicians and Surgeons of Canada 1990; 23:335
HSL4129
Williams AP, Cockerill R.
Report on the 1989 survey of the prescribing experiences and attitudes toward prescription drugs of Ontario physicians
1990;
HSL4130
Williams EB.
Advertising acyclovir
Lancet 1990; 335:288
HSL4131
Zaini J.
Pushing children’s vitamins
HAI News 1990; (51):1-2, 11
HSL4136
Cohen EP.
Are pharmaceutical ads good medicine?
Business and Society Review 1990; 73:8-10
HSL4137
Secunda E.
Is TV addicted to drug company PR?
Business and Society Review 1990; 73:11-14
HSL4145
Hamer P.
More medication for healthy women!
DES Action Canada Newsletter 1990; (23):1-2
www.web.net/~desact
HSL9482
Halperin JA.
Strategic issues in the Rx-to-OTC switch
Drug Information Journal 1990; 24:(1):13-18
HSL9483
Schondelmeyer SW.
Economic aspects of switch
Drug Information Journal 1990; 24:(1):57-66
HSL9488
Mela S.
European communities: outstanding white paper proposals for the completion of internal market in the pharmaceutical sector
Drug Information Journal 1990; 24:(3):635-638
HSL9490
Monk MR, Smith M.
Product portfolio analysis: SmithKline to SmithKline Beecham
Journal of Pharmaceutical Marketing Management 1990; 4:(4):85-96
HSL19871
Morris LA, Banks DB
New Issues in Drug Advertising and Labeling: The Five Advertising End-Runs
Drug Information Journal 1990; 24:639-646
http://dij.sagepub.com/content/24/3/639.abstract
HSL19057
Schwartz LM, Woloshin S.
Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988-1994.
Eff Clin Pract 1999; 2:(2):76-85.
http://www.acponline.org/clinical_information/journals_publications/ecp/marapr99/changing.htm
HSL19745
Ed.
Drug promotion: stealth, wealth, and safety.
Lancet 1993 12; 341:(8859):1507-8
http://www.sciencedirect.com/science/article/pii/014067369390637V
HSL19795
Huston P, Moher D.
Redundancy, disaggregation, and the integrity of medical research.
Lancet 1996 13; 347:(9007):1024-6
http://www.ncbi.nlm.nih.gov/pubmed/8606568
HSL19798
Wilmshurst P.
Publication bias.
Lancet 1991 8; 337:(8754):1419
http://www.sciencedirect.com/science/article/pii/014067369193110U
HSL19835
Brotzman GL, Mark DH.
The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities.
J Gen Intern Med 1993; 8:(3):130-4
http://www.ncbi.nlm.nih.gov/pubmed/8455108
HSL19855
McNeil JJ, Grabsch EA, McDonald MM
Postmarketing surveillance: strengths and limitations.The flucloxacillin-dicloxacillin story.
Med J Aust. 1999 Mar 15; 170:(60):270-3
http://www.ncbi.nlm.nih.gov/pubmed/10212650
HSL19861
Stauber J, Rampton S
The Public Relations Industry's Secret War on Activists
Covert Action Quarterly 1995
http://mediafilter.org/caq/Caq55.prwar.html
HSL19862
Caudill TS, Johnson MS, Rich EC, McKinney WP.
Physicians, pharmaceutical sales representatives, and the cost of prescribing.
Arch Fam Med 1996; 5:(4):201-6
http://www.ncbi.nlm.nih.gov/pubmed/8769907
HSL19872
Meyers D.
Doctors, research funds and marketing.
Med J Aust 1995 3; 162:(7):392
http://www.ncbi.nlm.nih.gov/pubmed/7715534
HSL19888
Skolnick AA.
WHO considers regulating ads, sale of medical products on Internet.
JAMA 1997 3; 278:(21):1723-4
http://www.ncbi.nlm.nih.gov/pubmed/9388131
HSL19899
McGavock H, Webb CH, Johnston GD, Milligan E.
Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.
BMJ 1993 30; 307:(6912):1118-20
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1679086/?tool=pubmed
HSL19900
Hogerzeil HV, Couper MR, Gray R.
Guidelines for drug donations.
BMJ 1997 8; 314:(7082):737-40
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2126144/?tool=pubmed
HSL19903
Schouten E
Drug donations must be strictly regulated. Georgia has tight guidelines.
BMJ 1995 9; 311:(7006):684
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551444/?tool=pubmed
HSL19908
Berckmans P, Dawans V, Schmets G, Vandenbergh D, Autier P.
Inappropriate drug-donation practices in Bosnia and Herzegovina, 1992 to 1996.
N Engl J Med 1997 18; 337:(25):1842-5
http://www.nejm.org/doi/full/10.1056/NEJM199712183372512
HSL19943
Davis I.
Inadvertent placement of advertisements.
Med J Aust 1994 6; 160:(11):727
http://www.ncbi.nlm.nih.gov/pubmed/8202012
HSL19970
Naeem S
Direct promotion to patients?
The Network of Association for Rational Use of Medication in Pakistan 1997 10
HSL19971
Bangash SM
Wrong claims and medical patronage
The Network of Association for Rational Use of Medication in Pakistan 1997
HSL20002
Drug Advertising Wars
Action Network (A Publication of the Australian Pensioners' & Superannuants' Federation 1996 Mar
HSL20006
Dodd P, Dexter T
Reasons for not seeing drug representatives. Companies have to encourage doctors to prescribe their products.
BMJ 1993 9; 319:(7215):69-70
http://www.ncbi.nlm.nih.gov/pubmed/10576840
HSL20013
Tiner R
Reasons for not seeing drug representatives: They should be seen because they are a good resource.
BMJ 1999 9; 319:(7215):1002
http://www.bmj.com/content/319/7215/1002?view=long&pmid=10514174
HSL20015
Newton-Syms FA, Dawson PH, Cooke J, Feely M, Booth TG, Jerwood D, Calvert RT.
The influence of an academic representative on prescribing by general practitioners.
Br J Clin Pharmacol 1992; 33:(1):69-73
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1381201/?tool=pubmed
HSL20031
Preston NW.
Publication bias via suppressed expert conflict.
Lancet 1993 17; 341:(8851):1031
http://www.ncbi.nlm.nih.gov/pubmed/8096921
HSL20040
Jorm AF.
Gifts from the pharmaceutical industry.
Med J Aust 1997 7; 166:(7):386-7
http://www.ncbi.nlm.nih.gov/pubmed/9137287
HSL20067
Halperin JA.
Medicine, pharmacy, and industry--a fly's eye view of health care.
Ann Pharmacother 1995; 29:(9):925-33
http://www.ncbi.nlm.nih.gov/pubmed/8547743
HSL20162
Tsao JC.
Informational and symbolic content of over-the-counter drug advertising on television.
J Drug Educ 1997; 27:(2):173-97
http://www.ncbi.nlm.nih.gov/pubmed/9270212
HSL20166
Law J
Preparing to advertise directly to the European consumer
Scrip 1999 Nov6
HSL20179
Collier J.
Conflicts between pharmaceutical company largesse and patients' rights.
Med Leg J 1992; 60:
http://www.ncbi.nlm.nih.gov/pubmed/1480006
Page 23 of 24 pages ‹ First < 21 22 23 24 >
